Search - tctmd.com

Displaying 1 - 16 of 16

Sort: Relevancy | Date

Podcast TCTMD Talking Points

The COBRA-REDUCE Trial

December 01, 2021

News Industry News

Essentials of Clinical Trial Design: Statistics 101 for the Budding Interventionalist

May 13, 2021

News Industry News

CeloNova Announces Late-Breaking Evidence from First-Ever Randomized Controlled Trial Evaluating 14-Days DAPT in Complex Patients at High Bleeding Risk Following PCI

October 17, 2020

Presentation TCT 2020

COBRA-REDUCE: Randomized Trial of COBRA PzF Stenting to REDUCE Duration of Triple Therapy

Presenter: Robert A. Byrne

October 17, 2020

Presentation TCT 2020

COBRA-REDUCE: A Randomized Trial of a Thromboresistant Polyzene F-Coated Stent With 14 Days DAPT in High-Bleeding Risk Patients

Presenter: Robert Byrne

October 17, 2020

News Conference News TCT 2020

Stent Polymer Face-off Calls Bioresorbable Coatings Into Question

Shelley Wood

October 17, 2020

News Opinion Editor's Corner TCT 2020

TCT 2020: Short DAPT, Longer TAVR Outcomes, Intravascular Imaging, and More

Shelley Wood

October 09, 2020

News Daily News

‘Speaking the Same Language’: New Guidance for Trials of Patients at High Bleeding Risk

Michael O'Riordan

September 16, 2020

News Industry News

CeloNova Announces Enrollment Completion of World’s First Randomized Control, 14-Day DAPT Trial

June 01, 2020

Presentation TCT 2019

COBRA REDUCE / MASTER DAPT

Presenter: Robert Byrne

September 27, 2019

News Industry News

CeloNova Announces Positive Clinical Results of eCOBRA Study at EuroPCR 2018

May 24, 2018

News Daily News

Cobra Stent With Ultrathin Polymer Safe, Effective but Needs Testing in Tougher Patients

Michael O'Riordan

February 03, 2017

News Industry News

CeloNova Announces FDA Approval to Start a Randomized Trial for the COBRA PzF™ Coronary Stent System

September 21, 2015

Video

» Topical Discussion

COBRA REDUCE Randomized Control Trial Results

March 4, 2021

Video

» Interview

COBRA-REDUCE: A Randomized Trial of a Thromboresistant Polyzene F-Coated Stent With 14 Days DAPT in High-Bleeding Risk Patients

October 17, 2020

Video

» Interview

ACC 2019: COBRA REDUCE Trial: Shortening DAPT Duration

March 21, 2019

Advertisement

The COBRA-REDUCE Trial

Essentials of Clinical Trial Design: Statistics 101 for the Budding Interventionalist

CeloNova Announces Late-Breaking Evidence from First-Ever Randomized Controlled Trial Evaluating 14-Days DAPT in Complex Patients at High Bleeding Risk Following PCI

COBRA-REDUCE: Randomized Trial of COBRA PzF Stenting to REDUCE Duration of Triple Therapy

COBRA-REDUCE: A Randomized Trial of a Thromboresistant Polyzene F-Coated Stent With 14 Days DAPT in High-Bleeding Risk Patients

Stent Polymer Face-off Calls Bioresorbable Coatings Into Question

TCT 2020: Short DAPT, Longer TAVR Outcomes, Intravascular Imaging, and More

‘Speaking the Same Language’: New Guidance for Trials of Patients at High Bleeding Risk

CeloNova Announces Enrollment Completion of World’s First Randomized Control, 14-Day DAPT Trial

COBRA REDUCE / MASTER DAPT

CeloNova Announces Positive Clinical Results of eCOBRA Study at EuroPCR 2018

Cobra Stent With Ultrathin Polymer Safe, Effective but Needs Testing in Tougher Patients

CeloNova Announces FDA Approval to Start a Randomized Trial for the COBRA PzF™ Coronary Stent System

COBRA REDUCE Randomized Control Trial Results

COBRA-REDUCE: A Randomized Trial of a Thromboresistant Polyzene F-Coated Stent With 14 Days DAPT in High-Bleeding Risk Patients

ACC 2019: COBRA REDUCE Trial: Shortening DAPT Duration

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content